Free Trial

STERIS (STE) Competitors

STERIS logo
$212.25 +0.25 (+0.12%)
(As of 11/20/2024 ET)

STE vs. BDX, EW, RMD, IDXX, DXCM, PODD, HOLX, BAX, GMED, and TFX

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Teleflex (TFX). These companies are all part of the "health care equipment" industry.

STERIS vs.

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

STERIS presently has a consensus target price of $253.00, indicating a potential upside of 19.20%. Becton, Dickinson and Company has a consensus target price of $283.00, indicating a potential upside of 27.25%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Becton, Dickinson and Company received 262 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.38% of users gave Becton, Dickinson and Company an outperform vote while only 58.98% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
STERISOutperform Votes
335
58.98%
Underperform Votes
233
41.02%
Becton, Dickinson and CompanyOutperform Votes
597
62.38%
Underperform Votes
360
37.62%

STERIS has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.7%. STERIS pays out 52.1% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 64.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.33B3.93$378.24M$4.3848.46
Becton, Dickinson and Company$20.18B3.19$1.73B$5.9437.44

In the previous week, Becton, Dickinson and Company had 10 more articles in the media than STERIS. MarketBeat recorded 28 mentions for Becton, Dickinson and Company and 18 mentions for STERIS. STERIS's average media sentiment score of 1.50 beat Becton, Dickinson and Company's score of 1.41 indicating that STERIS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
15 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
23 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Becton, Dickinson and Company has a net margin of 8.55% compared to STERIS's net margin of 8.02%. Becton, Dickinson and Company's return on equity of 14.89% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS8.02% 13.78% 8.28%
Becton, Dickinson and Company 8.55%14.89%6.98%

Summary

Becton, Dickinson and Company beats STERIS on 13 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$20.95B$9.70B$5.04B$19.90B
Dividend Yield1.04%1.10%5.17%3.54%
P/E Ratio48.4622.00122.4242.67
Price / Sales3.9330.911,179.2918.14
Price / Cash15.6923.3733.5617.85
Price / Book3.325.614.695.60
Net Income$378.24M$182.72M$118.98M$985.93M
7 Day Performance-4.49%44.47%-2.45%-0.19%
1 Month Performance-5.94%-7.33%-4.03%0.15%
1 Year Performance6.23%0.56%29.80%23.70%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.9928 of 5 stars
$212.25
+0.1%
$253.00
+19.2%
+6.2%$20.93B$5.14B48.4618,179Analyst Forecast
Positive News
BDX
Becton, Dickinson and Company
4.9899 of 5 stars
$222.41
-0.1%
$283.00
+27.2%
-4.8%$64.35B$20.18B37.4473,000Positive News
EW
Edwards Lifesciences
4.1259 of 5 stars
$69.54
-0.9%
$75.67
+8.8%
+3.5%$41.01B$6.00B10.0319,800Short Interest ↓
Analyst Revision
RMD
ResMed
4.797 of 5 stars
$241.55
+1.4%
$225.70
-6.6%
+59.7%$34.96B$4.69B31.999,980Positive News
IDXX
IDEXX Laboratories
4.8654 of 5 stars
$418.61
+0.5%
$552.38
+32.0%
-11.5%$34.09B$3.84B40.3711,000Positive News
DXCM
DexCom
4.9834 of 5 stars
$75.24
+0.5%
$104.59
+39.0%
-30.9%$29.25B$3.95B45.059,600
PODD
Insulet
4.3867 of 5 stars
$266.58
+1.8%
$253.27
-5.0%
+47.1%$18.38B$1.70B45.653,000
HOLX
Hologic
4.8572 of 5 stars
$78.04
-0.7%
$89.91
+15.2%
+8.5%$18.13B$4.03B23.446,990
BAX
Baxter International
4.8157 of 5 stars
$32.63
+0.3%
$40.91
+25.4%
-8.4%$16.60B$15.06B163.1560,000
GMED
Globus Medical
4.7045 of 5 stars
$83.58
+0.3%
$88.18
+5.5%
+84.2%$11.38B$1.57B124.755,000Analyst Downgrade
Positive News
TFX
Teleflex
4.8735 of 5 stars
$187.47
-2.9%
$259.25
+38.3%
-12.7%$8.97B$2.97B37.2714,500Analyst Downgrade

Related Companies and Tools


This page (NYSE:STE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners